Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
Hagopian W, Ferry RJ Jr, Sherry N, Carlin D, Bonvini E, Johnson S, Stein KE, Koenig S, Daifotis AG, Herold KC, Ludvigsson J; Protégé Trial Investigators. Hagopian W, et al. Among authors: herold kc. Diabetes. 2013 Nov;62(11):3901-8. doi: 10.2337/db13-0236. Epub 2013 Jun 25. Diabetes. 2013. PMID: 23801579 Free PMC article. Clinical Trial.
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Herold KC, et al. N Engl J Med. 2002 May 30;346(22):1692-8. doi: 10.1056/NEJMoa012864. N Engl J Med. 2002. PMID: 12037148 Free article. Clinical Trial.
Treatment of type 1 diabetes with anti-CD3 monoclonal antibody.
Glandt M, Hagopian W, Herold KC. Glandt M, et al. Among authors: herold kc. Rev Endocr Metab Disord. 2003 Dec;4(4):361-8. doi: 10.1023/a:1027354129493. Rev Endocr Metab Disord. 2003. PMID: 14618021 Review. No abstract available.
Insulin secretion in type 1 diabetes.
Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI, Donaldson D, Harlan DM, Bluestone J, Herold KC. Steele C, et al. Among authors: herold kc. Diabetes. 2004 Feb;53(2):426-33. doi: 10.2337/diabetes.53.2.426. Diabetes. 2004. PMID: 14747294 Clinical Trial.
A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D, Rother K, Diamond B, Harlan DM, Bluestone JA. Herold KC, et al. Diabetes. 2005 Jun;54(6):1763-9. doi: 10.2337/diabetes.54.6.1763. Diabetes. 2005. PMID: 15919798 Free PMC article. Clinical Trial.
Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC, Gitelman S, Greenbaum C, Puck J, Hagopian W, Gottlieb P, Sayre P, Bianchine P, Wong E, Seyfert-Margolis V, Bourcier K, Bluestone JA; Immune Tolerance Network ITN007AI Study Group. Herold KC, et al. Clin Immunol. 2009 Aug;132(2):166-73. doi: 10.1016/j.clim.2009.04.007. Epub 2009 May 14. Clin Immunol. 2009. PMID: 19443276 Free PMC article. Clinical Trial.
270 results